<DOC>
	<DOC>NCT00387829</DOC>
	<brief_summary>To evaluate the safety and effectiveness of DuraGen Plus® Adhesion Barrier Matrix as an adhesion barrier in spinal surgery to reduce the extent of peridural fibrosis formation and radicular pain in comparison to a control group receiving standard care.</brief_summary>
	<brief_title>DuraGen Plus® Adhesion Barrier for Use in Spinal Surgery</brief_title>
	<detailed_description>For more information, please visit www.DuragenStudy.com</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Spinal Injuries</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Inclusion Criteria (Abstracted from clinical protocol): Patients with radicular pain requiring singlelevel, lumbar hemilaminectomy or hemilaminotomy procedures with discectomy in the lower lumbar spine Require initial open lumbar surgery for extruded, prolapsed or bulging intervertebral discs Requires removal of herniated disc fragment Exclusion Criteria (Abstracted from clinical protocol): Current or historic open traumatic injury to the spine Any previous surgery to the lumbar spine or percutaneous tissue destruction or ablation procedures Women who are nursing, women who are pregnant and women who are planning to become pregnant during the time of the study Any spinal conditions or systemic diseases that would preclude the patient from participation in the clinical trial Clinically significant structural disorders Known positive for HIV Insulindependent Diabetes Mellitus patients Morbid obesity (Body Mass Index greater than or equal to 40 kg/m2) History of alcohol or drug abuse within 2 years prior to randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>